Initiate at OP: One Enovis, One Direction; FCF Inflection Could Drive Re-Rating

Research evidence excerpt

Initiate at OP: One Enovis, One Direction; FCF Inflection Could Drive Re-Rating

reaching the

25%+ 2026 target, eroding the financial credibility of the turnaround narrative. Surgeon uptake of ARVIS

Ultra is slower than expected due to competition from entrenched robotic platforms and the inherent

friction of workflow adoption, causing enabling technology to remain a headwind rather than a growth

driver in 2026–2027. The "One Enovis" cultural transformation takes longer than expected to implement,

cross-segment collaboration fails to gain traction, and the new CEO's strategic pivots remove assets that

were contributing more to earnings than the market appreciated. Lastly, under this scenario, Middle East

revenue exposure worsens beyond the current $1–2 million per month estimate, supply chain inflation

proves harder to absorb than management anticipates, and international procedure volumes remain soft

due to sustained healthcare worker strikes and rising waiting lists.

In the Exhibit Below, We Compare ENOV to Its MedTech Peers

Compared to its peers, the company is trading at a discount on 2027 estimates (6.3x vs. 13.0x), reflecting

the market's current skepticism around the FCF inflection story, and execution risk under a relatively new

CEO. We believe this discount is partially justified given the company's current leverage profile, below-

average FCF conversion, and the execution risk inherent in a multi-year operational transformation.

However, we also believe it is excessive relative to the fundamental quality of the Recon franchise, the

visibility of the FCF inflection, and the strength of the NPI pipeline. As management delivers on its near-

term operational milestones, particularly FCF conversion progress, ARVIS Ultra adoption, and leverage